Adelaide, Australia: LBT Innovations Limited, a pioneer in AI-driven microbiology automation, has announced a significant contract with NovaCina, a Perth-based CDMO.

The deal, valued at over $0.7 million, includes the sale of an APAS® Independence instrument equipped with APAS® PharmaQC software, and a five-year service agreement for software license, maintenance, and support.

The instrument is slated for delivery and installation at NovaCina’s aseptic manufacturing facility in June 2024.

This move aligns with NovaCina’s strategy to enhance operational efficiency and data integrity in environmental monitoring through AI automation.

This contract follows LBT’s recent sale to Thermo Fisher Scientific and marks a continued trend of early success in the biopharmaceutical market. The company’s sales have outpaced initial expectations by six months, reflecting strong commercial interest since the latter half of 2023.

Brent Barnes, CEO of LBT, expressed enthusiasm over the growing interest in their APAS® products, which are set to revolutionize workflow efficiencies in the biopharmaceutical sector. Brett Alderson, President of NovaCina, also highlighted the alignment of APAS® technology with their paperless operations and its anticipated role in supporting the company’s growth.

NovaCina, part of the Bridgewest Group, operates a cutting-edge facility in Perth, specializing in high-quality aseptic and terminally sterilised injectables, serving a global market for over three decades. The facility boasts a seasoned team and holds approvals from major health authorities worldwide.